The aim of this study is to summarize monitoring, prevention and treatment options of glucocorticoidinduced osteoporosis for patients on chronic glucocorticoid therapy.
INTRODUCTION
Osteoporosis is a disease of bone weakness leading to increased fracture risk. As a major cause of morbidity and mortality, it is an important public health concern and serious burden across the world. Secondary osteoporosis is bone loss caused by other medical conditions or treatments including medications. There is a growing list of medications that can result in bone fragility, with glucocorticoids being the most common. Through a combination of their widespread use and their frequent extended duration of use, glucocorticoidinduced osteoporosis (GIO) is currently the leading iatrogenic cause of osteoporosis. It is estimated that more than 10% of patients who receive long-term glucocorticoid treatment are diagnosed with a fracture [1] . Glucocorticoid-induced bone loss is most rapid in the first 6 months of steroid use, with a slower decline with chronic use. In addition to using as low of a dose and as short of a duration of glucocorticoids as possible, there are now guidelines for assessing fracture risk and treatments while patients are on glucocorticoids.
one of the most important hormones in the human body. Noncanonical pathways play less important roles, but these nongenomic effects have also been shown to contribute to various mechanisms of downregulating inflammatory markers [2] .
In terms of the direct impact on bone, endogenous glucocorticoids at physiologic concentrations may have a role in promoting osteogenesis [3] , while excess glucocorticoids increase osteoclastogenesis and suppress osteblastogenesis in cell culture, murine and human models [4, 5] . Local metabolism of glucocorticoids in bone cells is controlled by a pair of complementary enzymes, 11b-hydroxysteroid dehydrogenase types 1 and 2 (Hsd11b1 and Hsd11b2), which respectively activate or deactivate glucocorticoid action by metabolizing the interconversion of biologically active or inert forms [6, 7] . Additional pathways of glucocorticoid action are thought to be multiple, including inducing pro-apoptotic molecules in osteoblasts and osteocytes, and through antagonizing the osteoblastogenic Wnt pathway [4, 8, 9] . There continues to be active work into uncovering pathways of glucocorticoid mechanism at the cellular level [10] , including recent claims of enhancing osteoblast activity through heat shock protein 90 [11] .
In addition, there are indirect effects of glucocorticoids on skeletal health. They suppress Insulin-like growth factor 1, a hormone crucial for general growth [12] and bone and collagen formation [13] . They inhibit calcium absorption from the intestine. Effects of glucocorticoids on suppressing oestrogen and testosterone production may also augment deleterious effectsonbone.Finally,manyoftheunderlyingdisease states for which chronic glucocorticoids are prescribed are themselves linked to lower bone mineral density (BMD). Patients with Crohn's or cystic fibrosis are at risk of bone fragility due to malabsorption, and many conditions of chronic inflammation, such as rheumatoid arthritis or inflammatory bowel diseases, are associated with systemic increases in cytokines such as interleukin (IL)-6, Receptor activator of nuclear factor kappa-B ligand (RANKL) and IL-17, which drive the skeletal balance towards osteoclastogenesis [14] .
Pharmacologic preparations of glucocorticoids
Glucocorticoids are transported in the bloodstream bound to corticosteroid-binding globulin and albumin, in equilibrium with the biologically active free form that binds to the glucocorticoid receptor. Individual sensitivity to glucocorticoid signalling is also affected by genetic variability of the glucocorticoid receptor, with alternative splicing and polymorphisms identified [15, 16] . Furthermore, pharmaceutical preparations have differences in absorption, transport and target affinity, and thus a varied range of potencies and duration of effects. Glucocorticoid potency ranges from lower potency such as with cortisone and prednisone, to higher potency, such as with dexamethasone and betamethasone. In general, when oral cortisol (hydrocortisone) is used as a baseline, prednisone and prednisolone have about four times the potency, while methylprednisolone and triamcinolone are about five times the potency, and dexamethasone and betamethasone are about 25 times the potency. Reference charts of glucocorticoid potencies can be easily obtained [17] .
Most common forms of administered glucocorticoids are oral preparations. Intravenous, inhaled, injected and transdermal preparations are also frequently encountered. However, side effects, including to bone, are not limited to oral or intravenous administrations. Injected glucocorticoids, particularly when repeated, and topical therapy may both lead to systemic effects.
Clinical course of glucocorticoid-induced osteoporosis
The primary difference between GIO and postmenopausal osteoporosis is the suppression of osteoblastic activity, leading to decreased bone formation. However, an early phase consists of rapid loss of BMD due mostly to excessive bone resorption, while
KEY POINTS
Extra-physiologic doses of glucocorticoids suppress osteoblastogenesis and alter osteoclast activity.
Use of glucocorticoids at a dose equivalent of 2.5 mg of prednisone or greater for 3 months or longer leads to an increased fracture risk not completely reflected in bone mineral density measurement or T score, as glucocorticoids cause a disproportionate impairment in skeletal microarchitecture and quality.
A prior osteoporotic fracture, a T score of less than À2.5 in the hip or spine for men over age 50 or postmenopausal women, or a 10-year estimated risk of greater than 10% major osteoporotic fracture or 1% hip fracture based on FRAX, are qualifications for moderate to high risk.
For adults less than 40 years old, a Z score of less than À3 at the hip or spine, or rapid bone loss of more than 10% over 1 year, in addition to higher dose glucocorticoid use of greater than 7.5 mg equivalent a day, are qualifications for moderate risk.
Evidence supports use of bisphosphonates, teriparatide or denosumab in adults with moderate to high risk on chronic glucocorticoids. impaired bone formation usually manifests more progressively with long-term therapy. Trabecular bone loss predominates, with most marked changes not only in the lumbar spine, but also in the femoral neck and other sites. The effect on bone is dose dependent, with relative risk significantly increased at daily doses higher than 2.5 mg prednisolone equivalent [18] . It is also dependent on duration, with fracture risk returning to baseline months after cessation of therapy. However, changes to bone can occur sooner than many physicians realize. One study found that a 40 mg or higher prednisone equivalent a day can result in substantial BMD loss at the lumbar spine in just 2 months. [19] Metaanalyses indicate that exposure to steroid use is associated with a relative risk of fracture of about 1.6-1.98, and is independent of sex [20, 21] .
Fractures most often occur at sites enriched with trabecular (cancellous) bone, such as the lumbar spine and femoral neck. Vertebral fractures may be asymptomatic and detected only by radiographic imaging. Although much of the knowledge of GIO is extrapolated from experience with postmenopausal osteoporosis, it is important to note that fractures tend to occur at higher BMD in GIO [22] .
Risk stratification, screening and assessment
Management of patients who remain on glucocorticoids is based on risk modification and prevention of osteoporosis. The rate of screening for bone disease has traditionally varied by the medical specialty of the provider prescribing the chronic glucocorticoid [23] , but awareness has increased in recent years [24] . There are several groups with recommendations for identifying high risk of fracture in patients on glucocorticoids. Most determine an individual intervention threshold based on calculating a probability of fracture through using the Fracture Risk Assessment Tool score (FRAX), although there are other models [25] . The FRAX model has a built-in adjustment for glucocorticoid use. However, the BMD used in the FRAX tool is the femoral neck, while GIO more heavily affects sites with more trabecular bone such as the lumbar spine, so FRAX will underestimate the probability of fracture. Corroborating this, a study in Taiwan noted that glucocorticoid users have a higher probability of major osteoporotic fracture regardless of BMD [26] . Furthermore, FRAX cannot be used in people less than 40 years of age, so clinical judgement is required. Thus, adults younger than age 40 do not need BMD measurement unless a history of previous osteoporotic fracture or other risk factors are present, while all patients on chronic glucocorticoids over the age of 40 should have BMD and FRAX calculation within 6 months of initiation of glucocorticoids.
There are no clear data on frequency of BMD screening, but in general, BMD can be reassessed on the basis of the rate of bone loss of each patient. Patients recently starting glucocorticoids or those with multiple other risk factors or a history of fracture may need BMD measurement every 6 months, while those with more stability may have BMD measured as intermittently as once every 3 years.
Fracture risk as defined by the 2017 American College of Rheumatology Guidelines [27 && ] is calculated for those on prednisone equivalent of 2.5-7.5 mg/day, while those receiving higher doses should increase their major fracture risk by 15% and by 20% for the hip. For adults over age 40, the high-risk group is defined by those who have had prior osteoporotic fracture, or a total FRAX 10-year risk of more than 20% major fracture or more than 3% hip fracture, or for postmenopausal women and men over age 50, a hip or spine BMD T score less than À2.5. Moderate risk comprises those with 10-year major fracture risk of 10-19% or hip fracture risk of 1-3%, and low risk are those with less than 10% total and less than 1% hip fracture risks. For adults younger than age 40, high risk is any previous history of osteoporotic fracture, while moderate risk is a hip or spine BMD Z score of less than À3 or rapid bone loss of over 10% in the past year, in addition to high-dose chronic steroid use of more than 7.5 mg prednisone equivalent a day for greater than 6 months. These younger patients are otherwise considered low risk (Fig. 1) .
Treatment of patients on chronic glucocorticoids
All patients on glucocorticoids should have an adequate intake of vitamin D and calcium, with supplementation given if needed. Serum vitamin D levels should be maintained at a minimum of 20 ng/ml, if not higher. Lifestyle modifications are similar to those for postmenopausal osteoporosis, and include weight-bearing exercise and elimination of other risk factors such as smoking or alcohol abuse. The need for additional treatment is based on the risk stratification discussed above. Patients at moderate or high risk of osteoporosis are recommended to start pharmacologic agents. There is a plethora of evidence to support pharmacologic treatment in both men and women at a high risk of GIO. The first-line agent has been, and remains, bisphosphonate therapy. If bisphosphonates are contraindicated, teriparatide is a suggested as second-line agent, followed by denosumab.
Bisphosphonates, such as once-weekly oral alendronate or once-monthly oral ibandronate, have been the most studied agent for prevention and treatment of GIO. Most studies have focused on vertebral fractures as a primary endpoint, though BMD is frequently a proxy. A 2016 Cochrane review of 27 randomized control trials for bisphosphonates in chronic glucocorticoid users found a high certainty of evidence that bisphosphonates are beneficial in reducing the risk of vertebral fractures at 24 months of use, and moderate-certainty evidence of preventing bone loss at the lumbar spine and femoral neck [28 && ]. Several smaller studies published since then have also corroborated the efficacy of bisphosphonates in reducing bone mineral loss [29, 30] .
In addition to improving BMD or vertebral fracture risk, treatment can also reduce the risk of hip fractures. In a Swedish retrospective cohort study of patients aged 65 years or older who were on 3 months or more of at least 5 mg/day oral prednisolone, alendronate treatment resulted in a lower risk of hip fracture than no bisphosphonate treatment [31 && ]. Teriparatide (a recombinant PTH) has also been shown to reduce fracture risk, in fact, proving superior to alendronate in a comparison trial [32] . Another 2016 meta-analysis also found that teriparatide (as well as certain bisphosphonates) were associated with decreased vertebral fracture risk [33 & ]. In theory, as glucocorticoids do have a suppressive effect on osteoblasts, teriparatide would be an appropriate countermeasure as an anabolic agent. However, due to higher cost and inconvenience of administration, teriparatide remains in practice largely a second-line agent behind bisphosphonates in treating patients who are on glucocorticoids.
Denosumab, a RANKL inhibitor, has also been considered for prevention of GIO. Denosumab is given as a subcutaneous injection every 6 months, which may result in better adherence than oral bisphosphonate therapy [34] . However, data are more limited than that for use of bisphosphonates for GIO. Despite its proven efficacy in postmenopausal women [35] , there remain few studies specifically looking at GIO. One study of concurrent glucocorticoid and denosumab use in rheumatoid arthritis patients found increased lumbar spine and hip BMD [36] . A few small prospective studies of patients on glucocorticoids from Japan have found that lumbar spine, but not hip, BMD increased with denosumab treatment [37 & ,38] . In addition, a small study has shown preliminary data that switching from bisphosphonate to denosumab results in increased BMD while on long-term steroids, though the sample size was small and clinical fracture data were lacking [39] . Finally, care must be taken in patients with organ transplant (a common indication of chronic glucocorticoid use), as there are insufficient data on safety of denosumab in patients with multiple immunosuppressive agents.
Special consideration: children on steroids
Children represent a different approach, as bone development is still critical. In children, weight gain, growth retardation and Cushingoid features are the most frequent adverse reaction to chronic oral glucocorticoid use, but a recent meta-analysis that included a total of 6817 children noted a 21% incidence of decreased BMD [40 & ]. Growth retardation, whether directly or through suppression of the hypothalamic-pituitary axis or of sex steroid hormone production, puts children at a considerable risk of osteoporosis in adulthood, as peak bone mass is achieved in late adolescence and early adulthood. Although there are few prospective randomized controlled trials, there is general consensus for ensuring adequate calcium and vitamin D intake and for avoidance of further pharmacologic means such as bisphosphonates. Bisphosphonate use should only be considered, and even then very carefully, in children who have an osteoporotic fracture who are still continuing long-term glucocorticoid use.
For inhaled steroid use in children, commonly prescribed for asthma, most studies have not found effects of inhaled steroid use on bone markers [41] [42] [43] , although a few have identified decreased BMD with high-dose inhaled corticosteroids [44] . It is unclear whether there is confounding, as better control of asthma leads to greater physical activity, which is beneficial to bone development. It is now well accepted that no bone-specific monitoring or pharmacologic treatment is needed in intermittent or routine inhaled corticosteroid use for asthma, though 'periodic' evaluations of bone density may be advised in long-term, high-dose therapies [45] .
Future directions
In addition to solidifying evidence on teriparatide and denosumab use, there remain several avenues of work for alternate means of prevention and treatment of GIO. In a mouse model, activating Wnt/ beta-catenin signalling through a sclerostin knockout protected against the skeletal actions of excess glucocorticoids, hinting that sclerostin inhibitors may improve bone integrity in glucocorticoid use [46] . An antisclerostin antibody, romosozumab, recently completed phase III trials for use in postmenopausal osteoporosis, but has not come to market because of adverse effect safety concerns [47] .
In addition, the interplay between gut microbiota and bone remodeling has come to light. Recent studies have shown that microbiota affect bone physiology [48] , and that supplementation with probiotics can prevent oestrogen-deficiency induced osteoporosis in mice [49,50 & ] . A putative mechanism is through modulating intestinal permeability and thus T cell and inflammatory cytokine profile. If ongoing human trials can replicate an effect, the use of probiotics could be a low-cost method to prevent bone loss with few adverse effects, although whether or not its mechanism could be applied to glucocorticoid-induced osteoporosis is yet to be determined.
CONCLUSION
Glucocorticoid use of over 3 months duration leads to decreased BMD, primarily through osteoblast suppression, as well as through increasing osteoclast life span. Awareness of osteoporosis risk mandates the stratification of patients into low, moderate and high-isk categories. All patients should maintain adequate intake of calcium and vitamin D, while those in moderate and high-risk categories should initiate bisphosphonate therapy, or if bisphosphonates are contraindicated, use of alternative agents such as teriparatide or denosumab.
Li JY, Chassaing B, Tyagi AM, et al. Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest 2016; 126:2049-2063. This study definitively demonstrates the key role that microbiota play in maintaining bone homeostasis including in oestrogen deficiency, and shows that probiotics can prevent osteoporosis in mice. Microbiota manipulation through prebiotics, probiotics, antibiotics, or other means has become a hot topic and may result in new therapeutics for osteoporosis.
